Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-iCAP No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head Office: Sakyo-ku, Kyoto; Representative Director: Koji Murota) as unlimited liability partner, has recently made an investment in Chordia Therapeutics Inc. ("Chordia") (Head office: Fujisawa City, Kanagawa Prefecture; Representative Director: Hiroshi Miyake), a venture company utilizing research results from Kyoto University.

○Investment in Chordia
Chordia is a venture company founded by six researchers led by Dr. Miyake, a former leader in oncology drug discovery research at Takeda Pharmaceutical Company Limited. Chordia will take over several programs developed by the founders from Takeda. With this procurement, Chordia will promote the research and development of its own pipeline and collaborate with universities in Japan and overseas. Chordia's lead program, a CDC-like kinase ("CLK") inhibitor, regulates splicing reactions involved in the regulation of gene expression, and Chordia's scientific advisor, Professor Seiji Ogawa (Department of Tumor Biology, Graduate School of Medicine, Kyoto University), was the first in the world to discover splicing abnormalities in cancer via cancer genome analysis. Chordia and Professor Ogawa are leveraging their respective findings to advance the research and development of CLK inhibitors. Collaborative research on the creation of a treatment for adult T-cell leukemia-lymphoma (ATLL) is also underway between Chordia, Kyoto University, and Miyazaki University, supported by the Japan Agency for Medical Research and Development (AMED) Industry-Academia Collaboration Medical Innovation Creation Program.

Kyoto iCAP highly evaluated Chordia's management philosophy of delivering novel therapeutic drugs to patients suffering from refractory cancer and the potential of its pipeline, and has invested 250 million yen in Chordia in response to a private placement of new shares totaling approximately 1.2 billion yen. Takeda, SMBC Venture Capital, and Mitsubishi UFJ Capital will also participate in the private placement.

Chordia Therapeutics Corporation Overview

Establishment	October 12, 2017
Business	Research and development of novel anticancer agents
Head Office Location	Fujisawa City, Kanagawa Prefecture
President & CEO	Hiroshi Miyake